Neuroimaging of Peptide-based Vaccine Therapy in Pediatric Brain Tumors: Initial Experience

Overview

Journal Neuroimaging Clin N Am

Specialties Neurology
Radiology

Date 2016 Nov 28

PMID 27889021

Citations 6

Authors

Andre D Furtado

Rafael Ceschin

Stefan Bluml

Gary Mason

Regina I Jakacki

Hideho Okada

Ian F Pollack

Ashok Panigrahy

Affiliations

Soon will be listed here.

Abstract

The potential benefits of peptide-based immunotherapy for pediatric brain tumors are under investigation. Treatment-related heterogeneity has resulted in radiographic challenges, including pseudoprogression. Conventional MR imaging has limitations in assessment of different forms of treatment-related heterogeneity, particularly regarding distinguishing true tumor progression from efficacious treatment responses. Advanced neuroimaging techniques, including diffusion magnetic resonance (MR), perfusion MR, and MR spectroscopy, may add value in the assessment of treatment-related heterogeneity. Observations suggest that recent delineation of specific response criteria for immunotherapy of adult brain tumors is likely relevant to the pediatric population and further validation in multicenter pediatric brain tumor peptide-based vaccine studies is warranted.

Citing Articles

Advanced MRI Protocols to Discriminate Glioma From Treatment Effects: State of the Art and Future Directions.

Malik D, Rath T, Urcuyo Acevedo J, Canoll P, Swanson K, Boxerman J Front Radiol. 2023; 2:809373.

PMID: 37492687 PMC: 10365126. DOI: 10.3389/fradi.2022.809373.

Magnetic Resonance Spectroscopy Metabolites as Biomarkers of Disease Status in Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG) Treated with Glioma-Associated Antigen Peptide Vaccines.

Panigrahy A, Jakacki R, Pollack I, Ceschin R, Okada H, Nelson M Cancers (Basel). 2022; 14(23).

PMID: 36497477 PMC: 9739009. DOI: 10.3390/cancers14235995.

Current Clinical and Pre-Clinical Imaging Approaches to Study the Cancer-Associated Immune System.

Mueller C, Gaiddon C, Venkatasamy A Front Immunol. 2021; 12:716860.

PMID: 34539653 PMC: 8446654. DOI: 10.3389/fimmu.2021.716860.

Considerations when treating high-grade pediatric glioma patients with immunotherapy.

Crotty E, Downey K, Ferrerosa L, Flores C, Hegde B, Raskin S Expert Rev Neurother. 2020; 21(2):205-219.

PMID: 33225764 PMC: 7880880. DOI: 10.1080/14737175.2020.1855144.

Current and Future Imaging Methods for Evaluating Response to Immunotherapy in Neuro-Oncology.

Kasten B, Udayakumar N, Leavenworth J, Wu A, Lapi S, McConathy J Theranostics. 2019; 9(17):5085-5104.

PMID: 31410203 PMC: 6691392. DOI: 10.7150/thno.34415.

References

Panigrahy A, Bluml S . Neuroimaging of pediatric brain tumors: from basic to advanced magnetic resonance imaging (MRI). J Child Neurol. 2009; 24(11):1343-65. DOI: 10.1177/0883073809342129. View

Hattingen E, Raab P, Franz K, Zanella F, Lanfermann H, Pilatus U . Myo-inositol: a marker of reactive astrogliosis in glial tumors?. NMR Biomed. 2007; 21(3):233-41. DOI: 10.1002/nbm.1186. View

van Waarde A, Elsinga P . Proliferation markers for the differential diagnosis of tumor and inflammation. Curr Pharm Des. 2008; 14(31):3326-339. DOI: 10.2174/138161208786549399. View

Spence A, Muzi M, Link J, OSullivan F, Eary J, Hoffman J . NCI-sponsored trial for the evaluation of safety and preliminary efficacy of 3'-deoxy-3'-[18F]fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studies. Mol Imaging Biol. 2009; 11(5):343-55. PMC: 4739628. DOI: 10.1007/s11307-009-0215-2. View

Ullrich R, Backes H, Li H, Kracht L, Miletic H, Kesper K . Glioma proliferation as assessed by 3'-fluoro-3'-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma. Clin Cancer Res. 2008; 14(7):2049-55. DOI: 10.1158/1078-0432.CCR-07-1553. View

Srinivasan R, Phillips J, VandenBerg S, Polley M, Bourne G, Au A . Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM. Neuro Oncol. 2010; 12(11):1152-61. PMC: 3098023. DOI: 10.1093/neuonc/noq075. View

Enslow M, Zollinger L, Morton K, Butterfield R, Kadrmas D, Christian P . Comparison of 18F-fluorodeoxyglucose and 18F-fluorothymidine PET in differentiating radiation necrosis from recurrent glioma. Clin Nucl Med. 2012; 37(9):854-61. PMC: 3525078. DOI: 10.1097/RLU.0b013e318262c76a. View

Bartha R, Megyesi J, Watling C . Low-grade glioma: correlation of short echo time 1H-MR spectroscopy with 23Na MR imaging. AJNR Am J Neuroradiol. 2008; 29(3):464-70. PMC: 8118860. DOI: 10.3174/ajnr.A0854. View

Schepkin V, Lee K, Kuszpit K, Muthuswami M, Johnson T, Chenevert T . Proton and sodium MRI assessment of emerging tumor chemotherapeutic resistance. NMR Biomed. 2006; 19(8):1035-42. PMC: 3140794. DOI: 10.1002/nbm.1074. View

10.

Calamante F . Perfusion MRI using dynamic-susceptibility contrast MRI: quantification issues in patient studies. Top Magn Reson Imaging. 2011; 21(2):75-85. DOI: 10.1097/RMR.0b013e31821e53f5. View

11.

Choi S, Kim J, Kim J, Oh S, Lee J, Kim C . [18F]3'-deoxy-3'-fluorothymidine PET for the diagnosis and grading of brain tumors. Eur J Nucl Med Mol Imaging. 2005; 32(6):653-9. DOI: 10.1007/s00259-004-1742-3. View

12.

Kitahara S, Nakasu S, Murata K, Sho K, Ito R . Evaluation of treatment-induced cerebral white matter injury by using diffusion-tensor MR imaging: initial experience. AJNR Am J Neuroradiol. 2005; 26(9):2200-6. PMC: 7976122. View

13.

van Waarde A, Jager P, Ishiwata K, Dierckx R, Elsinga P . Comparison of sigma-ligands and metabolic PET tracers for differentiating tumor from inflammation. J Nucl Med. 2006; 47(1):150-4. View

14.

Poussaint T, Kocak M, Vajapeyam S, Packer R, Robertson R, Geyer R . MRI as a central component of clinical trials analysis in brainstem glioma: a report from the Pediatric Brain Tumor Consortium (PBTC). Neuro Oncol. 2011; 13(4):417-27. PMC: 3064695. DOI: 10.1093/neuonc/noq200. View

15.

Boada F, Tanase C, Davis D, Walter K, Torres-Trejo A, Couce M . Non-invasive assessment of tumor proliferation using triple quantum filtered 23/Na MRI: technical challenges and solutions. Conf Proc IEEE Eng Med Biol Soc. 2007; 2004:5238-41. DOI: 10.1109/IEMBS.2004.1404464. View

16.

Cha S . Dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in pediatric patients. Neuroimaging Clin N Am. 2006; 16(1):137-47, ix. DOI: 10.1016/j.nic.2005.11.006. View

17.

Pollock J, Tan H, Kraft R, Whitlow C, Burdette J, Maldjian J . Arterial spin-labeled MR perfusion imaging: clinical applications. Magn Reson Imaging Clin N Am. 2009; 17(2):315-38. PMC: 2735771. DOI: 10.1016/j.mric.2009.01.008. View

18.

Negendank W, Sauter R . Intratumoral lipids in 1H MRS in vivo in brain tumors: experience of the Siemens cooperative clinical trial. Anticancer Res. 1996; 16(3B):1533-8. View

19.

Yamamoto Y, Ono Y, Aga F, Kawai N, Kudomi N, Nishiyama Y . Correlation of 18F-FLT uptake with tumor grade and Ki-67 immunohistochemistry in patients with newly diagnosed and recurrent gliomas. J Nucl Med. 2012; 53(12):1911-5. DOI: 10.2967/jnumed.112.104729. View

20.

Pollack I, Jakacki R, Butterfield L, Hamilton R, Panigrahy A, Normolle D . Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas. Neuro Oncol. 2016; 18(8):1157-68. PMC: 4933485. DOI: 10.1093/neuonc/now026. View